KRAS and pancreatic adenocarcinoma: To confirm these findings, we examined the tumor histology and pathology reports through the Cancer Digital Slide Archive (http://cancer.digitalslidearchive.net) and found that although the majority of KRAS mutant TCGA-PAAD patients with heterozygous loss of BAP1 harbored mutations of TP53 and developed PDA, 6/7 patients with wild-type TP53 presented with pancreatic cancer arising from IPMNs and MCNs (Fig. 4d and Supplementary Fig. 4g).